TITLE

Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment

AUTHOR(S)
Roux, Perrine; Carrieri, M. Patrizia; Cohen, Julien; Ravaux, Isabelle; Poizot-Martin, Isabelle; Dellamonica, Pierre; Spire, Bruno
PUB. DATE
November 2009
SOURCE
Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, p1433
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of individuals infected with HIV (as a result of injection drug use) and receiving HAART to investigate the predictors of long-term virological success. Design. Data were collected every 6 months from outpatient hospital services delivering HIV care in France. We selected all patients who were receiving HAART for at least 6 months (baseline visit) and who had indications for OST (ie, still dependent on opioids). We selected a total of 113 patients, accounting for a total of 562 visits for all the analyses. Methods. Long-term virological success was defined as an undetectable viral load after at least 6 months on HAART. Retention in OST was defined as the time interval between the last initiation or reinitiation of OST during HAART follow-up and any given visit on OST. A mixed logistic model was used to identify predictors of long-term virological success. Results. At baseline, 53 patients were receiving buprenorphine, 28 patients were receiving methadone, and 32 patients were not on OST. The median duration of OST was 25 months (range, 3-42 months). In the multivariate analysis, after adjustment for significant predictors of long-term virological success such as adherence to HAART and early virological response, retention in OST was associated with long-term virological success (odds ratio, 1.20 per 6-month increase; 95% confidence interval, 1.09-1.32). Conclusions. Our study presents important evidence of the positive impact of retention in OST on HIV outcomes. Increasing access to OST based on a comprehensive model of care for HIV-infected patients who have indications for OST may foster adherence and ensure long-term response to HAART.
ACCESSION #
45122068

 

Related Articles

  • Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Bernardini, Claudia; Maggiolo, Franco // Patient Preference & Adherence;2013, Vol. 7, p531 

    The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food...

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

  • Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Letendre, Scott; Ellis, Ronald J.; Best, Brookie; Bhatt, Archana; Marquie-Beck, Jennifer; LeBlanc, Shannon; Rossi, Steven; Capparelli, Edmund; McCutchan, J. Allen // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Jun2009, Vol. 8 Issue 2, p169 

    Combination antiretroviral therapy (ART) has markedly reduced morbidity and mortality among HIV-infected individuals but not the prevalence of HIV-associated neurocognitive disorders (HAND). Several conditions may be responsible for the high prevalence of cognitive impairment, including...

  • Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Gutierrez, Absalon; Balasubramanyam, Ashok // Endocrine (1355008X);Feb2012, Vol. 41 Issue 1, p1 

    HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased...

  • Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis? van der Kop, Mia L. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p3 

    The article presents a case study that examines the association of HIV and its treatment with antiretroviral therapy (ART) on multiple sclerosis (MS). Topics discussed include use of data of HIV patients between 1999 and 2011 followed up with records of MS, authors of the study showing that the...

  • Loss of correlation between HIV viral load and CD4 + T-cell counts in HIV/HTLV-1 co-infection in treatment naïve Mozambican patients. Bhatt, N. B.; Gudo, E. S.; Semá, C.; Bila, D.; Di Mattel, P.; Augusto, O.; Garsia, R.; Jani, I. V. // International Journal of STD & AIDS;Dec2009, Vol. 20 Issue 12, p863 

    Summary: Seven hundred and four HIV-1 /2-positive, antiretroviral therapy (ART) naïve patients were screened for HTLV-1 infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients. Each co-infected individual was matched with two HIV mono-infected patients according to World...

  • Optimal timing for initiation of antiretroviral therapy: a prospective study on treatment naive HIV patients. Chakravarty, Jaya; Singh, Avinash; Singh, Anup; Rai, Madhukar; Gupta, Anoop; Agarwal, Amit; Sundar, Shyam // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a prospective study on the optimal timing for initiation of antiretroviral therapy in naive HIV patients. The authors observed the immunological disease progression of patients for 1 year, which resulted to higher number of opportunistic infection in patients. They indicate...

  • Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy? Vasudevan, Janani; Sivasankar, Vaishnavi; Rao, Umadevi K.; Kumarasamy, Nagalingeswaran; Ranganathan, Kannan // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a study on the prevalence of oral lesions among HIV seropositive individuals in India. The authors investigate the prevalence of oral lesions among HIV patients on Highly Active Antiretroviral Therapy (HAART). They state that patients under HAART have fewer orals lesions,...

  • HIV-1 RNA May Decline More Slowly in Semen than in Blood following Initiation of Efavirenz-Based Antiretroviral Therapy. Graham, Susan M.; Holte, Sarah E.; Dragavon, Joan A.; Ramko, Kelly M.; Mandaliya, Kishor N.; McClelland, R. Scott; Peshu, Norbert M.; Sanders, Eduard J.; Krieger, John N.; Coombs, Robert W.; Lama, Javier R. // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Objectives: Antiretroviral therapy (ART) decreases HIV-1 RNA levels in semen and reduces sexual transmission from HIV-1- infected men. Our objective was to study the time course and magnitude of seminal HIV-1 RNA decay after initiation of efavirenz-based ART among 13 antiretroviral-naïve...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics